Cargando…

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

BACKGROUND: Real-world studies of disease-modifying therapies (DMTs) in multiple sclerosis (MS) have reported suboptimal adherence. OBJECTIVE: We aimed to describe treatment patterns, relapses, healthcare resource utilization, and costs in MS patients experiencing their first observed DMT switch. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freeman, Leorah, Kee, Arianna, Tian, Marc, Mehta, Rina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605953/ https://www.ncbi.nlm.nih.gov/pubmed/34136997 http://dx.doi.org/10.1007/s40801-021-00251-w

Ejemplares similares

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients
por: Freeman, Leorah, et al.
Publicado: (2021)

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Bowen, James, et al.
Publicado: (2020)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
por: Nicholas, Jacqueline, et al.
Publicado: (2017)

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
por: Goldberg, Lawrence, et al.
Publicado: (2009)

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients
por: Calocer, Floriane, et al.
Publicado: (2018)

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
por: Bonafede, Machaon, et al.
Publicado: (2020)

Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
por: Burks, Jack, et al.
Publicado: (2017)

Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications
por: Tseng, Yi-Ju, et al.
Publicado: (2017)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database
por: Kawachi, Izumi, et al.
Publicado: (2019)

Dense module searching for gene networks associated with multiple sclerosis
por: Manuel, Astrid M., et al.
Publicado: (2020)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
por: Becker III, Russell V., et al.
Publicado: (2011)

Healthcare costs and resource utilization of asthma in Germany: a claims data analysis
por: Jacob, Christian, et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis
por: Cappell, Katherine, et al.
Publicado: (2020)

Cost of managing an episode of relapse in multiple sclerosis in the United States
por: O'Brien, Judith A, et al.
Publicado: (2003)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani, Divaya, et al.
Publicado: (2017)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysis
por: Cheng, Ssu-Wei, et al.
Publicado: (2018)

Health care utilizations and costs of Campylobacter enteritis in Germany: A claims data analysis
por: Schorling, Elisabeth, et al.
Publicado: (2023)

Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011–2015
por: Blozik, Eva, et al.
Publicado: (2017)

Second Banff Workshop debates discovery claims
Publicado: (2010)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
por: Fernández, Oscar
Publicado: (2012)

Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
por: Hernandez, Luis, et al.
Publicado: (2020)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
por: Nicholas, Jacqueline, et al.
Publicado: (2020)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Effects of conformance to type 2 diabetes guidelines on health care resource utilization, clinical outcomes, and cost: A retrospective claims analysis
por: Mehta, Rajesh R., et al.
Publicado: (2020)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014)

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
por: Fernández, Oscar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3d7i01tk7uu3ceqknq1513c4mn